Blockchain Registration Transaction Record

Cardio Diagnostics Partners with IBN to Advance AI-Powered Heart Disease Solutions

Cardio Diagnostics partners with IBN to advance AI-powered cardiovascular disease prevention and detection solutions using epigenetics and genetics for personalized medicine approaches.

This partnership matters because cardiovascular disease remains the leading cause of death globally, claiming nearly 18 million lives annually. Traditional risk assessment methods often lack precision and accessibility, leaving many at risk undetected until symptoms appear. Cardio Diagnostics' innovative approach combining epigenetics, genetics and artificial intelligence represents a paradigm shift toward personalized, predictive medicine. Their blood-based tests could enable earlier intervention and more targeted prevention strategies, potentially reducing healthcare costs and saving lives. The engagement with IBN's extensive communications network suggests the company is preparing for broader market awareness and adoption, which could accelerate the availability of these advanced diagnostic tools to healthcare providers and patients worldwide.